Clinical Trial Update: Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection [Phase 4]

View source ↗

Summary

A Phase 4 study comparing fidaxomicin to standard of care in solid organ transplant recipients with Clostridium difficile infection has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection
• Solid Organ Transplant

Drugs mentioned

• Fidaxomicin (fidaxomicin)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Clostridium Difficile Infection, Solid Organ Transplant | Phase 4 | Status: WITHDRAWN